key: cord-0305777-8s8j8r3s
authors: Kumar, Sonu; Lin, Xiaohe; Ngo, Timothy; Shapero, Benjamin; Sou, Cindy; Allen, Joel D.; Copps, Jeffrey; Zhang, Lei; Ozorowski, Gabriel; He, Linling; Crispin, Max; Ward, Andrew B.; Wilson, Ian A.; Zhu, Jiang
title: Neutralizing antibodies induced by first-generation gp41-stabilized HIV-1 envelope trimers and nanoparticles
date: 2020-12-02
journal: bioRxiv
DOI: 10.1101/2020.12.02.408328
sha: 6d089ede6d64b8f1199512814c55f6eb0651b812
doc_id: 305777
cord_uid: 8s8j8r3s

Antigen-specific B-cell sorting and next-generation sequencing (NGS) were combined to isolate HIV-1 neutralizing antibodies (NAbs) from mice and rabbits immunized with BG505 trimers and nanoparticles. Three mouse NAbs potently neutralize BG505.T332N and recognize a glycan epitope centered at the C3/V4 region, as revealed by electron microscopy (EM), x-ray crystallography, and epitope mapping. Three potent NAbs were sorted from rabbit B cells that target glycan holes on the BG505 envelope glycoprotein (Env) and account for a significant portion of autologous NAb response. We then determined a 3.4Å-resolution crystal structure for the clade C transmitted/founder Du172.17 Env with a redesigned heptad repeat 1 (HR1) bend. This clade C Env, as a soluble trimer and attached to a ferritin nanoparticle, along with a clade A Q482-d12 Env trimer, elicited distinct NAb responses in rabbits. Our study demonstrates that nanoparticles presenting gp41-stabilized trimers can induce potent NAb responses in mice and rabbits with Env-dependent breadth. TEASER Mouse and rabbit NAbs elicited by gp41-stabilized trimers and nanoparticles neutralize autologous HIV-1 by targeting different epitopes

Mouse and rabbit NAbs elicited by gp41-stabilized trimers and nanoparticles neutralize autologous 26 HIV-1 by targeting different epitopes 27 28

Antigen-specific B-cell sorting and next-generation sequencing (NGS) were combined to isolate 30 HIV-1 neutralizing antibodies (NAbs) from mice and rabbits immunized with BG505 trimers and 31 nanoparticles. Three mouse NAbs potently neutralize BG505.T332N and recognize a glycan 32 epitope centered at the C3/V4 region, as revealed by electron microscopy (EM), x-ray 33 crystallography, and epitope mapping. Three potent NAbs were sorted from rabbit B cells that 34 target glycan holes on the BG505 envelope glycoprotein (Env) and account for a significant 35 portion of autologous NAb response. We then determined a 3.4Å-resolution crystal structure for 36 the clade C transmitted/founder Du172.17 Env with a redesigned heptad repeat 1 (HR1) bend. This 37 clade C Env, as a soluble trimer and attached to a ferritin nanoparticle, along with a clade A Q482-38 d12 Env trimer, elicited distinct NAb responses in rabbits. Our study demonstrates that 39 nanoparticles presenting gp41-stabilized trimers can induce potent NAb responses in mice and 40 rabbits with Env-dependent breadth. 41

After structural characterization and glycan analysis of three design platforms for this clade 426 C Env, we assessed two Du172.17 Env immunogens along with a UFO-BG trimer designed for a 427 tier 2 clade A T/F strain, Q842.d12, in three groups of rabbits. To maximize the outcome of in vivo 428 assessment for Du172.17 Env, we tested a Du172.17 UFO-BG trimer and a FR NP presenting the 429 structurally defined Du172.17 gp140.664.R4 trimer (Fig. 4A) . Of note, the same regimen was used 430 to facilitate comparison with the previous BG505 immunization (Fig. 3A) (37). We first assessed 431 rabbit plasma at the last time point (week 30) against an expanded panel of viruses including the 432 respective autologous virus (either Du172.17 or Q842-d12), BG505.T332N, tier 1 SF162, and the 433 12-virus global panel, with MLV included as a control ( Fig. 4D and fig. S9 ). Overall, distinct 434 neutralization patterns were observed compared to the previous BG505 immunization (Fig. 3B) . 435

Using a 100-fold starting dilution, autologous NAb responses were not observed for any group 436 except for the plasma from RB50 in the Du172.17 trimer group, which also neutralized all tested 437 HIV-1 isolates and exhibited a detectable non-specific response to MLV ( fig. S9A) . The lack of 438 autologous neutralization here therefore differed significantly from our previous study (37), where 439 a robust autologous NAb response was observed for three of four rabbits in the BG505 440 gp140.664.R1-FR group (Fig. 3B) . Furthermore, the clade C Du172.17 trimer and FR NP elicited 441 consistently, albeit slightly, stronger NAb responses to clade A p398F1 than did their clade A 442 BG505 counterparts, using a 40-fold starting dilution. Weak but consistent plasma neutralization 443 was also developed against other isolates such as clade C p25710 and clade B pX2278 in rabbits 444 immunized with the clade C Du172.17 gp140.664.R4-FR NP, but less so in the other two trimer 445 groups irrespective of the Env origin. In terms of tier 1 NAb response, the clade A Q842-d12 trimer 446 elicited the most potent response with ID50 values of 344 to 1554, whereas the clade C Du172.17 447 gp140.664.R4-FR NP yielded ID50 values of 162 or lower. As multiple studies have shown that 448 21 BG505 Env mainly induced autologous NAb responses to glycan holes, our current study indicated 449 that other Envs may elicit a broader response with the potential to neutralize more HIV-1 isolates. 450

Pre-immunization (-d10) samples exhibited negligible reactivity on the 12-virus panel, indicating 451 a clean background ( fig. S9) . Lastly, we characterized the longitudinal NAb development for the 452 clade C Du172.17 trimer and FR groups ( Fig. 4E and fig. S10 ). The soluble trimer elicited a more 453 rapid tier 1 NAb response to clade B SF162 than the gp140-FR NP and, for most time points, this 454 response also appeared to be more potent than the NP-induced tier 1 NAb response (Fig. 4E, left) . 455

However, the tier 2 NAb response to clade A p398F1 exhibited a distinct pattern compared to the 456 tier 1 NAb response, with plasma neutralization (measured by ID50) only observed for week 14 457

and onwards (Fig. 4E , right). The difference in such a tier 2 response was not significant between 458 trimer and FR groups, likely due to the small group size and the outlier (RB50) in the trimer group. 459

The crystal structure of a novel tier 2 clade C T/F Env confirmed the effectiveness of HR1 460 redesign in trimer stabilization. The rabbit study on three Env immunogens derived from two T/F 461 Envs of different subtypes suggested that the BG505-elicited glycan hole NAb responses may be 462 specific to BG505 Env and that other HIV-1 Envs may achieve a broader NAb response. However, 463 elicitation of a potent bNAb response remains a challenge for HIV-1 vaccine design. The success of BG505 SOSIP.664 trimer as a structural template to study bNAb-Env interactions 468 and as an Env backbone to experiment with various rational designs has led to a plethora of studies 469 that position native-like Env trimers at the center of HIV-1 vaccine research (12, 20) . However, 470 some fundamental questions related to the inherent features of HIV-1 Env need to be addressed to 471 guide future vaccine development (90). Critical issues related to trimer design, particulate display 472 platforms, and animal models for vaccine evaluation, will remain open questions while multiple 473 vaccine strategies continue to be explored in parallel. 474

In this follow-up study, we examined some of these issues by utilizing animal samples 475 generated in our previous study (37) and by conducting new immunization experiments. First, we 476 provide evidence at the monoclonal level that potent tier 2 NAbs can be elicited in the wildtype 477 mouse model using a multivalent Env immunogen. The nsEM model and crystal structure of NAb 478 M4H2K1 in complex with BG505 Env identified a target for potent mouse NAbs -an epitope that 479 is recognized by the autologous NAb response in early human infection (5). Together with another 480 cross-clade NAb, M1H3K3, our study indicates that wildtype mice provide a useful small animal 481 model for testing HIV-1 vaccines. However, the non-specific antiviral component in mouse serum 482 poses a challenge for pseudovirus neutralization assays and has been the source of inconsistencies 483 in recent studies (37, 44, 45, 91) . Thus, purified IgG must be used to unambiguously demonstrate 484 the elicitation of tier 2 NAbs in mouse immunization (37). Since the tier 2 NAb response can be 485 readily observed in rabbits and such NAbs often target glycan holes, wildtype mice may offer a 486 more advantageous animal model for evaluating HIV-1 vaccine designs and understanding their 487 immunologic mechanisms, as shown in recent studies of multivalently displayed Envs in mice (91-488 93). Second, we provide evidence at the monoclonal level that BG505 Env bearing a redesigned 489 HR1N segment (the core of the UFO trimer design (19)), both as a soluble trimer and on a 24-490 meric FR NP, can induce potent tier 2 NAbs, which, however, are mostly directed to the known 491 glycan holes (55, 59). Display of BG505 trimers on this small protein NP did not broaden the 492 autologous NAb response in rabbits (37) (Fig. 3B) 

Expression and purification of HIV-1 Env probes, trimers, and gp140 nanoparticles 520

The Avi-tagged BG505 gp140.664.R1 trimer probe was transiently expressed in HEK293F cells 521 (Thermo Fisher) (67). Env protein was purified from the supernatant by a Galanthus nivalis lectin 522 (GNL) column (Vector Labs) and eluted with PBS containing 500 mM NaCl and 1 M methyl-α-523 D-mannopyranoside. Biotinylation was performed using the BirA biotin-protein ligase standard 524 reaction kit (BirA-500) as per the manufacturer's instructions (Avidity). This BG505 trimer probe 525 was further purified by SEC on a HiLoad 16/600 Superdex 200 PG column (GE Healthcare). A 526 ferritin (FR) NP presenting BG505 V1V2 and a trimeric scaffold (1TD0) presenting ZM109 V1V2 527 were transiently expressed in N-acetylglucosaminyltransferase I-negative (GnTI -/-) HEK293S cells 528 (Thermo Fisher) (41). Both FR and I3-01 NPs presenting an N332-scaffold, 1GUT_A_ES, were 529 transiently expressed in HEK293F cells treated with Kifunensine (TOCRIS Bioscience) (69). Both 530 V1V2 and N332 epitope probes were extracted from the supernatant using a GNL column. Fusion 531 peptide (FP) probes were created by fusing the FP motif, AVGIGAVFL, to a FR or 1TD0 subunit 532 with a 5GS (G4S) linker. The FP-5GS-FR and BG505 gp120-FR probes were transiently expressed 533 in ExpiCHO cells (Thermo Fisher) using a similar protocol to BG505 gp140 NPs (37). The trimeric 534 FP-5GS-1TD0 probe was also transiently expressed in ExpiCHO cells. Immunoaffinity columns 535 based on bNAbs VRC34 (99) and PGT145 (100) were used to extract two FP probes (FP-5GS-FR 536 NP and FP-5GS-1TD0 trimer) and the BG505 gp120-FR probe from the supernatant, respectively. 537

After purification using a GNL or antibody column, the NP and 1TD0-derived epitope probes were 538 further purified by SEC on a Superose 6 10/300 GL column and a Superdex 75 10/300 GL column 539 25 (GE Healthcare), respectively. For rabbit immunization, the Du172.17 UFO-BG trimer, the FR NP 540 presenting a structurally defined Du172.17 gp140.664.R4 trimer, which is cleaved and contains a 541 redesigned HR1 (HR1-#4 (19)), and the Q842-d12 UFO-BG trimer were transiently expressed in 542

ExpiCHO cells (37). For the two UFO-BG trimers, Env protein was extracted from the supernatant 543 by a GNL column and trimer was purified by SEC on a HiLoad 16/600 Superdex 200 PG column. 544

The Du172.17 gp140.664.R4-FR NP was purified using a 2G12 affinity column (14) followed by 545 SEC on a Superose 6 10/300 GL column. Protein concentrations were determined using ultraviolet 546 absorbance at 280 nm (UV280) with theoretical extinction coefficients. 547

Mouse spleen cells harvested 15 days after the last injection were prepared for sorting. 

Antibody cloning of Env-sorted single B cells was conducted as follows. A mix containing 3 µl 573 Random Hexamers (GeneLink), 2 µl dNTPs, and 1 µl of the SuperScript IV enzyme (Thermo 574 Fisher) was added to each well of a single-cell sorted 96-well plate that underwent thermocycling 575 according to the program outlined in the SuperScript IV protocol resulting in 25 µl of cDNA for 576 each single cell. 5 µl of cDNA was then added to a PCR mix containing 12.5 µl 2× Multiplex PCR 577 mix (Qiagen), 9 µl H2O, 0.5 µl of forward primer mix, and 0.5 µl of reverse primer mix (mouse 578 (101) and rabbit (55)) for heavy and κ-light chains within each well. A second PCR reaction was 579 then performed using 5 µl of the first PCR as template and respective primers (mouse (101) and 580 rabbit (55)) utilizing the same recipe as the first PCR. The PCR products were run on 1% Agarose 581 gel and those with correct heavy and light chain bands were then used for Gibson ligation (New 582

England Biolabs), cloning into IgG expression vectors, and transformation into competent cells. 583

Mouse and rabbit mAbs were expressed by transient transfection of ExpiCHO cells (Thermo 584 27 Fisher) with equal amount of paired heavy and κ-light chain plasmids and purified from the culture 585 supernatant after 12-14 days using Protein A beads columns (Thermo Fisher). 586

We combined the 5′-rapid amplification of cDNA ends (RACE) protocol with previously reported 588 heavy and κ-light chain primers for mouse (101) and rabbit (84) to facilitate NGS analysis of Env-589 specific mouse splenic B cells and rabbit B cells, respectively. Briefly, 5´-RACE cDNA was 590 obtained from bulk-sorted B cells of each animal with SMART-Seq v4 Ultra Low Input RNA Kit 591 for Sequencing (TaKaRa). The Ig PCRs were set up with Platinum Taq High-Fidelity DNA 592

Polymerase (Thermo Fisher) in a total volume of 50 µl, with 5 μl of cDNA as template, 1 μl of 5´-593 RACE primer, and 1 μl of 10 µM reverse primer. The 5′-RACE primer contained a PGM/S5 P1 594 adaptor, while the reverse primer contained a PGM/S5 A adaptor. For mouse samples, we adapted 595 the mouse 3´-Cγ1-3/3´-Cµ inner primers and 3´-mCκ outer primer (101) as reverse primers for 5´-596 RACE PCR processing of heavy and κ-light chains, respectively. For rabbit samples, we adapted 597 rabbit RIGHC1/RIGHC2 primers and RIGkC primers (84) as reverse primers for 5´-RACE PCR 598 processing of heavy and κ-light chains, respectively. A total of 25 cycles of PCR was performed 599 and the expected PCR products (500-600 bp) were gel purified (Qiagen). NGS was performed on 600 the Ion S5 GeneStudio platform. Briefly, heavy and κ-light chain libraries from the same animal 601 were quantitated using Qubit® 2.0 Fluorometer with Qubit® dsDNA HS Assay Kit, and then 602 mixed at a ratio of 2:1 or 3:1 before being pooled with antibody libraries from the other animals at 603 an equal ratio. Template preparation and Ion 530 chip loading were performed on Ion Chef using 604 the Ion 520/530 Ext Kit, followed by sequencing on the Ion S5 system with default settings. The 605 mouse antibodyomics pipeline (69) was used to process the mouse NGS data. The rabbit 606 antibodyomics pipeline was created by incorporating rabbit germline genes from IMGT 607 28 (http://www.imgt.org/) into the reference libraries. Quantitative repertoire profiles were generated 608 for germline gene usage, degree of SHM, and H/KCDR3 loop length. The two-dimensional (2D) 609 divergence/identity plots were generated to visualize selected mouse and rabbit NAb/mAb chains 610 in the context of Env-specific B cell repertoires. A previously described sequence clustering 611 algorithm (67) was used to derive consensus heavy and κ-light chains for prevalent antibody 612 lineages from NGS data of bulk-sorted mouse splenic B cells. NGS-derived mAbs were transiently 613 expressed in ExpiCHO cells (Thermo Fisher) with equal amount of heavy and κ-light chain 614 plasmids and purified from culture supernatants after 12-14 days using Protein A beads columns 615 (Thermo Fisher). 616

Each well of a Costar TM 96-well assay plate (Corning) was first coated with 50 µl PBS containing 618 0.2 µg of the appropriate antigens. The plates were incubated overnight at 4 °C, and then washed 619 five times with wash buffer containing PBS and 0.05% (v/v) Tween 20. Each well was then coated 620 with 150 µl of a blocking buffer consisting of PBS, 40 mg ml -1 blotting-grade blocker (Bio-Rad), 621 and 5% (v/v) FBS. The plates were incubated with the blocking buffer for 1 hour at room 622 temperature, and then washed five times with wash buffer. For antigen binding, antibodies were 623 diluted in the blocking buffer to a maximum concentration of 10 µg ml -1 followed by a 10-fold 624 dilution series. For each antibody dilution, 50 µl was added to the appropriate wells. Next, a 1:5000 625 dilution of goat anti-human IgG antibody (Jackson ImmunoResearch Laboratories, Inc) was made 626 in the wash buffer (PBS containing 0.05% Tween 20), with 50 µl of the diluted secondary antibody 627 added to each well. The plates were incubated with the secondary antibody for 1 hour at room 628 temperature, and then washed five times with PBS containing 0.05% Tween 20. Finally, the wells 629 were developed with 50 µl of TMB (Life Sciences) for 3-5 min before stopping the reaction with 630 29 50 µl of 2 N sulfuric acid. The resulting plate readouts were measured at a wavelength of 450 nm. 631

The EC50 values were calculated in GraphPad Prism 8.4.3. 632

Pseudoviruses were generated by transfection of HEK293T cells with an HIV-1 Env expressing 634 plasmid and an Env-deficient genomic backbone plasmid (pSG3ΔEnv), as previously described 635 Expression, purification of BG505 gp120 core, Du172.17 gp140, Fabs and complex formation 657

The antigen-binding fragments (Fabs) of M4H2K1, 17b, PGT124, and 35O22 were expressed in 658

FreeStyle HEK293F cells (Invitrogen) and purified by CaptureSelect CH1-XL affinity (Thermo 659 Fisher) chromatography followed by SEC on a Superdex 75 16/600 column (GE Healthcare). The 660 BG505 gp120 core protein was transiently expressed in FreeStyle HEK293S cells, extracted from 661 the supernatant using a GNL affinity column, followed by SEC on a Superdex 200 16/600 column 662 (GE Healthcare). A complex was formed by combining gp120:M4H2K1:17b in a 1:2:2 molar ratio, 663 followed by deglycosylation using endoH digestion (New England Biolabs) at 37 °C for 1 hour 664 before SEC purification. The gp120:M4H2K1:17b complex was then analyzed by sodium dodecyl 665 sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The clade C Du172.17 gp140.664.R4 666

Env trimer was expressed in FreeStyle HEK293S cells. Env protein was harvested from media and 667 purified with a 2G12 column (14) followed by SEC on a Superdex 200 column (GE Healthcare). 668

The Du172.17 trimer complex was formed by mixing PGT124 and 35O22 Fabs in a molar ratio of 669 1:3.5:3.5 (Du172:PGT124:35O22) at room temperature for 30 min. The trimer complex was then 670 partially deglycosylated using endoH digestion (New England Biolabs) (23) at 37 °C for 1 hour 671 and then purified on a Superdex 200 column. The complex was SEC-purified in 50 mM Tris-HCl, 672

150mM NaCl (pH = 7.4) and concentrated to ∼10 mg/ml prior to crystallization trials. 673

The SEC-purified Fab M4H2K1 and complex were each concentrated to 12 mg/ml before being 675 screened at both 4 °C and 20 °C using our high-throughput CrystalMation TM robotic system 676 31 (Rigaku) at TSRI (103). High-quality crystals of unbound Fab M4H2K1 were grown in 0.1 M 677 CHES (pH = 9.5) and 36% PEG600 at 4 °C, and M4H2K1 bound gp120 core complex in 0.1 M 678

Tris (pH = 7), 1.825 M ammonium sulfate, 0.29 M lithium sulfate, and 15% ethylene glycol at 20 679 °C. Crystals were harvested, and followed by immediate flash cooling in liquid nitrogen. The 680

Du172.17 trimer complex was set up at both 4 °C and 20 °C using our Rigaku CrystalMation TM 681 robotic system. High-quality crystals of Fabs PGT124 and 35O22 bound to the HR1-redesigned 682

Du172.17 trimer were obtained in 0.1 M Tris (pH = 8.4), 25% (v/v) PEG400 at 20 °C. Data were 683 collected at Advanced Photon Source (APS) on beamlines 23-IDD and 23-IDB. 684

The unbound Fab M4H2K1 and the Fab M4H2K1-BG505 gp120 core -Fab 17b crystals diffracted 686 to 1.50 Å and 4.30 Å resolution, respectively. The data were indexed, integrated and scaled using 687 HKL2000 (104) in P3121 for unbound M4H2K1-Fab and in P21212 for the complex. The unbound 688

Fab structure was solved by molecular replacement (MR) using Phaser (105) Privateer (118). Data collection and refinement statistics are shown in Table S1 . 709

Complexes of M4H2K1 Fab and BG505 UFO.664 trimer were purified by SEC to remove 711 unbound Fab and diluted to 0.01 mg/mL in Tris-buffered saline prior to adsorption onto carbon-712 coated and plasma cleaned copper mesh grids (Cu400, Electron Microscopy Sciences). Grids were 713 stained with 2% (w/v) uranyl formate for about 60 s and imaged on an FEI Tecnai Spirit 714 microscope operating at 120 keV, equipped with a TVIPS TemCam F416 4k × 4k CMOS camera. 715 Automated data collection was performed using Leginon (119). Particles were picked using 716 DogPicker in the Appion software suite (120), extracted using Relion 3.0 (121), and imported into 717 cryoSPARC v2 (122). After one round each of 2D and 3D classification, 14,027 particles were 718 included in a 3D refinement with C3 symmetry imposed and a low pass-filtered volume of ligand-719 free HIV-1 Env used as the initial model. The final resolution for the negative-stain reconstruction 720 is estimated to be ~25 Å (Fourier shell correlation cutoff of 0.5). 721

Three 50 μg aliquots of each sample were denatured for 1h in 50 mM Tris/HCl, pH 8.0 containing 723 6 M of urea and 5 mM dithiothreitol (DTT). Next, Env proteins were reduced and alkylated by 724 adding 20 mM iodoacetamide (IAA) and incubated for 1h in the dark, followed by a 1h incubation 725 with 20 mM DTT to eliminate residual IAA. The alkylated Env proteins were buffer-exchanged 726 into 50 mM Tris/HCl, pH 8.0 using Vivaspin columns (3 kDa) and digested separately overnight 727 using trypsin, chymotrypsin or elastase (Mass Spectrometry Grade, Promega) at a ratio of 1:30 728 (w/w). The next day, the peptides were dried and extracted using C18 Zip-tip (MerckMilipore). 729

The peptides were dried again, re-suspended in 0.1% formic acid and analyzed by nanoLC-ESI 730 MS with an Easy-nLC 1200 (Thermo Fisher Scientific) system coupled to a HexNAc(4)X to A2/A1B, HexNAc(5)X to A3/A2B, and HexNAc(6)X to A4/A3B. If all of these 757 compositions had a fucose, they are assigned to the corresponding FA category. Note that this 758 analytical approach does not distinguish between isomers, which could influence the formal 759 assignment of number of antennae in some cases. 760

The Institutional Animal Care and Use Committee (IACUC) guidelines were followed with animal 762 subjects tested in the immunization study. Rabbit immunization and blood sampling were carried 763 out under a subcontract at Covance (Denver, PA) following a previously described protocol (37). 764

Three groups of female New Zealand White rabbits, four rabbits per group, were immunized 765 intramuscularly with 30 µg of trimer or NP formulated in 250 µl of adjuvant AddaVax (InvivoGen) 766 with a total volume of 500 µl, at weeks 0, 4, 12, 20, and 28. Blood samples, 15 ml each time, were 767 35 collected at day -10, weeks 1, 6, 14, 22, 28, and 30. Plasma was separated from blood and heat 768 inactivated for ELISA binding and TZM-bl neutralization assays. 769

Supplementary material for this article is available at XXX. 771 -ETVDNYGISF AAS QQSKEVPWT a Mice 1-4 were immunized with an I3-01 nanoparticle presenting 20 gp41-stabilized BG505 trimers, with mice 1 and 4 showing robust neutralization of a tier-2 autologous isolate, BG505.T332N. b M1H1 sequence does not have the "WGXG" motif and the typical "VSS" C-terminal motif, but is included for the sake of completeness in the NGS analysis. c M4-Ab3 and Ab9 were isolated from mouse 4 by antigen-specific single-cell sorting using a BG505 trimer bait. 

A 99.7% a Listed items include the mouse sample ID, number of raw reads (N Raw ), number of sequences after V H /V K gene assignment and removing fragments with a V-gene alignment of 250bp or shorter (N Align ), Chain type (H or K), number of V H /V K chains, average read length of specific chain type, number of usable full-length antibody chains after the Antibodyomics pipeline processing (N Usable ), and percentage of usable chains (Perc Usable =N Usable /N Chain ×100%). NGS was performed on Ion S5 using an Ion 530 chip. 58.4% a Listed items include the mouse sample ID, number of raw reads (N Raw ), number of sequences after V H /V K gene assignment and removing fragments with a V-gene alignment of 250bp or shorter (N Align ), Chain type (H or K), number of V H /V K chains, average read length of specific chain type, number of usable full-length antibody chains after the Antibodyomics pipeline processing (N Usable ), and percentage of usable chains (Perc Usable =N Usable /N Chain ×100%). NGS was performed on Ion S5 using an Ion 530 chip. SOSIP   N88  N130  N139  N142  N148  N156  N160  N186  N189  N197  N230  N234  N241  N262  N276  N289  N295  N301  N332  N339  N355  N392  N406  N412  N442  N448  N463  N611  N618  N625 UFO  N88  N130  N139  N142  N148  N156  N160  N186  N189  N197  N230  N234  N241  N262  N276  N289  N295  N301  N332  N339  N355  N392  N406  N412  N442  N448  N463  N611  N618  N625 

A Group 1 rabbit plasma neutralization against MLV, SF162 and BG505.T332N at -d10 and w30

Group 1 rabbit plasma neutralization against the 12-virus global panel at -d10 and w30

C Group 2 rabbit plasma neutralization against MLV, SF162 and BG505.T332N at -d10 and w30

Group 2 rabbit plasma neutralization against the 12-virus global panel at -d10 and w30 

Antibody responses to envelope glycoproteins in HIV-1 787 infection

HIV-1 vaccines based on antibody identification, B cell 789 ontogeny, and epitope structure

Recent progress in broadly neutralizing antibodies to HIV

HIV broadly neutralizing antibody targets. Curr

The C3-V4 region is a major target of autologous neutralizing 795 antibodies in human immunodeficiency virus type 1 subtype C infection

Early low-titer neutralizing antibodies impede HIV-1 replication and 798 select for virus escape

Specificity of the autologous neutralizing antibody 800 response

Limited neutralizing antibody specificities drive neutralization escape 802 in early HIV-1 subtype C infection

Strategies for a multi-stage neutralizing 804 antibody-based HIV vaccine

Antibodies in HIV-1 vaccine development and therapy

B-cell-lineage immunogen design 808 in vaccine development with HIV-1 as a case study

Native-like Env trimers as a platform for HIV-1 vaccine 810 design

HIV-1 envelope trimer design and 812 immunization strategies to induce broadly neutralizing antibodies

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 815 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-816 neutralizing antibodies

A native-like SOSIP.664 trimer based on an HIV-1 subtype B Env gene

Design and structure of two HIV-1 clade C SOSIP.664 trimers that 820 increase the arsenal of native-like Env immunogens

High-density array of well-ordered HIV-1 spikes on synthetic liposomal 886 nanoparticles efficiently activate B cells

Neutralizing antibody induction by HIV-1 envelope glycoprotein 888 SOSIP trimers on iron oxide nanoparticles may be impaired by mannose binding lectin

Murine antibody responses to cleaved soluble HIV-1 envelope trimers are 891 highly restricted in specificity

Immunization expands B cells specific to HIV-1 V3 glycan in mice 893 and macaques

Epitope-based vaccine design yields fusion peptide-directed antibodies that 895 neutralize diverse strains of HIV-1

HIV vaccine design to target germline precursors of glycan-897 dependent broadly neutralizing antibodies

Specifically modified Env immunogens activate B-cell precursors 899 of broadly neutralizing HIV-1 antibodies in transgenic mice

Sequential immunization elicits broadly neutralizing anti-HIV-1 902 antibodies in Ig knockin mice

HIV-1 neutralizing antibodies induced by native-like envelope 904 trimers

Vaccine induction of heterologous tier 2 HIV-1 neutralizing 906 antibodies in animal models

Immunogenicity in rabbits of HIV-1 SOSIP trimers from clades A, 908

given individually, sequentially, or in combination

Vaccine-elicited tier 2 HIV-1 neutralizing antibodies bind to 911 quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site

Holes in the glycan shield of the native HIV envelope are a target of 914 trimer-elicited neutralizing antibodies

Elicitation of neutralizing antibodies targeting the V2 apex of the HIV 916 envelope trimer in a wild-type animal model

Closing and opening holes in the glycan shield of HIV-1 envelope 918 glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly 919 unmasked epitopes

Sequential and simultaneous immunization of rabbits with HIV-1 921 envelope glycoprotein SOSIP.664 trimers from clades A, B and C

Epitopes for neutralizing antibodies induced by HIV-1 envelope 924 glycoprotein BG505 SOSIP trimers in rabbits and macaques

Cleavage-independent HIV-1 trimers from CHO cell lines elicit robust 927 autologous tier 2 neutralizing antibodies

Electron-microscopy-based epitope mapping defines specificities of 929 polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization

Quantification of the impact of the HIV-1-glycan shield on antibody 932 elicitation

Elicitation of robust tier 2 neutralizing antibody responses in 934 nonhuman primates by HIV envelope trimer immunization using optimized approaches

Extensive dissemination and intraclonal maturation of HIV Env 937 vaccine-induced B cell responses

Mapping the immunogenic landscape of near-native HIV-1 envelope 939 trimers in non-human primates

Mapping neutralizing antibody epitope specificities to an HIV Env 941 trimer in immunized and in infected rhesus macaques

Hidden lineage complexity of glycan-dependent HIV-1 broadly 943 neutralizing antibodies uncovered by digital panning and native-like gp140 trimer

A VH1-69 antibody lineage from an infected Chinese donor potently 946 neutralizes HIV-1 by targeting the V3 glycan supersite

Differential antibody responses to conserved HIV-1 neutralizing 948 epitopes in the context of multivalent scaffolds and native-like gp140 trimers

Key gp120 glycans pose roadblocks to the rapid development of VRC01-951 class antibodies in an HIV-1-infected Chinese donor

Global panel of HIV-1 Env reference strains for standardized 953 assessments of vaccine-elicited neutralizing antibodies

Structure and immune recognition of trimeric pre-fusion HIV-1 Env. 955

Structural basis for broad and potent neutralization of HIV-1 by antibody 957 VRC01

Networks of HIV-1 envelope glycans maintain antibody epitopes 959 in the face of glycan additions and deletions

Supersite of immune vulnerability on the glycosylated face of HIV-1 961 envelope glycoprotein gp120

Broadly neutralizing antibody 8ANC195 recognizes closed and open 963 states of HIV-1 Env

Structure of an HIV gp120 envelope glycoprotein in complex with 965 the CD4 receptor and a neutralizing human antibody

Affinity maturation of a potent family of HIV antibodies is primarily 967 focused on accommodating or avoiding glycans

Disruption of the HIV-1 envelope allosteric network blocks CD4-969 induced rearrangements

Natively glycosylated HIV-1 Env structure reveals new mode for 971 antibody recognition of the CD4-binding site

The HIV-1 envelope glycoprotein C3/V4 region defines a prevalent 973 neutralization epitope following immunization

Antibody responses elicited by immunization with BG505 trimer 975 immune complexes

Autologous antibody responses to an HIV envelope glycan hole are 977 not easily broadened in rabbits

Systematic 979 characterization and comparative analysis of the rabbit immunoglobulin repertoire

Global trends in 982 molecular epidemiology of HIV-1 during

Capturing the inherent structural dynamics of the HIV-1 envelope 984 glycoprotein fusion peptide

Germline VRC01 antibody recognition of a modified clade C HIV-1 986 envelope trimer and a glycosylated HIV-1 gp120 core

Targeted selection of HIV-specific antibody mutations by 988 engineering B cell maturation

The modern era of HIV-1 vaccine development

Env exceptionalism: why are 992 HIV-1 Env glycoproteins atypical immunogens?

Engineered immunogen binding to alum adjuvant enhances humoral 994 immunity

Multifaceted effects of antigen valency on B cell response composition 996 and differentiation in vivo

Enhancing humoral responses against HIV envelope trimers via 998 nanoparticle delivery with stabilized synthetic liposomes

Self-assembling nanoparticles presenting receptor binding domain and 1000 stabilized spike as next-generation COVID-19 vaccines. bioRxiv

Single-component multilayered self-assembling nanoparticles presenting 1003 rationally designed glycoprotein trimers as Ebola virus vaccines. bioRxiv

Role of nanoscale antigen organization on B-cell activation probed 1006 using DNA origami

Proof of concept for rational design of hepatitis C virus E2 core 1008 nanoparticle vaccines

Nanoparticle size influences antigen retention and presentation in 1010 lymph node follicles for humoral immunity

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

Broad neutralization coverage of HIV by multiple highly potent 1014 antibodies

Cloning and expression of murine Ig genes from 1016 single B cells

Optimization and validation of the TZM-bl assay for 1018 standardized assessments of neutralizing antibodies against HIV-1

The JCSG high-throughput structural biology pipeline

Processing of X-ray diffraction data collected in oscillation 1023 mode

Phaser crystallographic software

Crystal structures of mono-and bi-specific diabodies and reduction of 1027 their structural flexibility by introduction of disulfide bridges at the Fv interface

Early antibody lineage diversification and independent limb 1030 maturation lead to broad HIV-1 neutralization targeting the Env high-mannose patch

A new family of small-molecule CD4-mimetic compounds contacts highly 1033 conserved aspartic acid 368 of HIV-1 gp120 and mediates antibody-dependent cellular 1034 cytotoxicity

Broad and potent HIV-1 neutralization by a human antibody that binds 1036 the gp41-gp120 interface

Structural evolution of glycan recognition by a family of potent HIV 1038 antibodies

Recent developments in the PHENIX software for automated 1040 crystallographic structure determination

Coot: model-building tools for molecular graphics

Structural analysis of glycoproteins: building N-linked glycans 1044 with Coot

MolProbity: all-atom structure validation for macromolecular 1046 crystallography

Accessing the Kabat antibody sequence database by computer

Complete nucleotide sequences of functional clones of the AIDS virus

pdb-care (PDB carbohydrate residue check): a program 1052 to support annotation of complex carbohydrate structures in PDB files

Strategies for carbohydrate model building, refinement and validation

Automated molecular microscopy: The new Leginon system

Appion: An integrated, database-driven pipeline to facilitate EM 1059 image processing

New tools for automated high-resolution cryo-EM structure 1061 determination in RELION-3

cryoSPARC: algorithms for 1063 rapid unsupervised cryo-EM structure determination

We thank Y. Hua, H. Tien, R. Stanfield, and Drs. X. Dai, and M. Elsliger

 TGGCCTTGAGTGGATTGGAGATGTTTACCCTGGAGACGGTTTTACTCAGAACAATGAGAAGTTCAAGGACAAGGCCACACTGACTGCAGACAAATCCTCCAGCACATCCTACAGGCAGCTCAGCAGTC  TGACATCTGAGGAATCTGCGGTCCATTACTGTTCGACACCTACGGTAGTGCCTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA  >M4H2  GAAGTGAAGCTTGAGGAGTCCGGAGGAGGCTTGGTGCAACCTGGAGGATCCATGAAACTCTCCTGTGTTGCCTCTGGAATCACTTTCAGTAACTCCTGGATGAGCTGGGTCCGCCAGTCTCCAGAGAA  GGGGCTTGAGTGGGTTGCTGAAATTAGATTGAAAGCTCAAAATTATGCAACACATTATGCGGCGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGACTCCAAAAGTAGTGTCTACCTACAAATGA  ACAACTTAAGACCTGAAGACACTGGCATCTATTACTGTACCACCCCACTGGGAGGCTATTTTGATATGGACTACTGGGGTCAAGGAACCTCACTCACCGTCTCCTCA  >M4K1  GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGCGAAAGTGTTGATATTTATGGCATTAGTTTTATGAACTGGTTCCAACAGAG  ACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAACCGAGGATCCGGGGTCCCTGCCAGGTTTAGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTATGGAGGAGGATG  ATACTGCAATGTATTTCTGTCAGCAAAGTAAGGAGGTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA  >M4K2  CAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGACCTGCAGTGCCAGCTCAAGTGTAAGTTACATGTCTTGGTACCAGCAGAAGCCAGGATCCTCCCC  CCGACTCCTGATTTATGACACATCCGACCTGGCTTCTGGAGTCCCTTTTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATT  ACTGCCAACAGTGGGATCCTTACCCGCTCACGTTCGGTTCTGGGACCAAGCTGGAGCTGAAA  >M4K3 GACATTGTGATGTCACAGTCTCCATCCTCCCTAGCTGTGTCAGTTGGAGAGAAGGTTACTATGAGCTGCAAGTCCAGTCAGAGCCTTTTATATAGTAGCAATCAAAAGAACTACTTGGCCTGGTACCA GCAGAAACCAGGGCAGTCTCCTAAACTGCTGATTTACTGGGCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGAAGG CTGAAGACCTGGCAGTTTATTACTGTCAGCAATATTATAGCTATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA a The antibody chain sequences were identified from the NGS of Env-specific splenic B cells using a clustering algorithm and consensus as described in detail in the Methods. b Nucleotide that was modified to remove a stop codon is colored in red and underscored.

QIVLTQSPRIMSASPGERVTVTCSASSSVSYMSWYQQKPGSSPRLLIFDTSNLASGVPFRFSGSGSGTSYSLTISRMEAEDAATYCCQQWSRYPFTFGSGTKLEIK Antibody chains from mouse 4 in the I3-01 groupDIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK a The amino acid sequences were translated from the nucleotide sequences using TRANSEQ. b HCDR3 and framework 4 (FR4) region missing the "WGXG" motif and "VSS" motifs are highlighted in gray shading. Nucleotide sequences of two antibodies identified from splenic B cells of mouse 4 (M4) in the I3-01 group by Env-specific single-cell sorting a >M4-Ab3H CAGGTGCAGCTGCAGCAGCCTGGAGGAGGCTCGGTGCAACCTGGAGGATCCATGAAACTCTCCTGTGTTGCCTCTGGATTCACCTTCAGTAATTCCTGGATGAACTGGGTCCGCCAGTCTCCAGAGAA GGGGCTTGAGTGGGTTGCTGAAATTCGATTGAAAGTTCATAATTATGCAACACATTATGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGATTCCAAAAGTAGTGTCTACCTGCAAATGA TCAACTTAAGACCAGAAGACACTGGCATTTATTATTGTACTACCCCACTGGGTGGCTACTTTCCTATGGACTACTGGGGTCAAGGAACCACTCTCACAGTCTCCTCA >M4-Ab3K GACATTGTGCTGACCCAATCTCCAACTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGCGAAAGTGTTGATAATTATGGCGTTAGTTTTATGAACTGGTTCCAACAGAA ACCAGGACGGCCACCCAAACTCCTCATCTATGCTGCATCCAAGCAAGGATCCGGGGTCCCTGCCAGGTTTAGTGGCAGTGGGTCTGGGACAGATTTCAGCCTCAACATCCATCCAATGGAGGAGGATG ATATTGCAATGTATTTCTGTCAGCAAAATAAGGAGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA >M4-Ab9H AGGGTGCAGCTGCAGCAGTCTTGTGGAGGCTTGGTGCAACCTGGAGGATCCATGAAACTCTCCTGCGTTGCCTCTGGAATCACTTTCAGTAACTCCTGGATGAACTGGGTCCGCCAGTCTCCAGAGAA GGGGCTTGAGTGGGTTGCTGAAATTAGATTGAAAGTTAATAATTATGCAACACATTATGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGATTCCAAAAGGAGTGTCTACCTGCAAATGA ACAACTTAAGAGCTGAAGACACTGGCATTTATTACTGTACCACCCCACTGGGTGGCTACTATGCTGTGGACTACTGGGGTCAAGGAGCCACTCTCACAGTCTCCTCA >M4-Ab9K GACATCCAGATGATTCAGTCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGCGAAAGTGTTGATAATTATGGCATTAGTTTTATGAACTGGTTCCAACAGAA ACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAACCAAGGATCCGGGGTCCCTGCCAGGTTTAGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTATGGAGGAGGATG ATACTGCAATGTATTTCTGTCAGCAAAGTAAGGAGGTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA a The antibody chain sequences were identified from Env-specific single-cell sorting, PCR and cloning as described in the Methods. 2 b Calculated as average(I)/average(σI) c Rsym = ΣhklΣi | Ihkl,i -<Ihkl> | / ΣhklΣiIhkl,I, where Ihkl,i is the scaled intensity of the i th measurement of reflection h, k, l, <Ihkl> is the average intensity for that reflection, and n is the redundancy. Rpim is a redundancy-independent measure of the quality of intensity measurements. Rpim = Σhkl (1/(n-1)) 1/2 Σi | Ihkl,i -<Ihkl> | / Σhkl Σi Ihkl,I, where Ihkl,i is the scaled intensity of the i th measurement of reflection h, k, l, < Ihkl > is the average intensity for that reflection, and n is the redundancy. d Rcryst = Σhkl | Fo -Fc | / Σhkl | Fo | × 100 e Rfree was calculated as for Rcryst, but on a test set comprising 5% of the data excluded from refinement. f These values were calculated using MolProbity (http://molprobity.biochem.duke.edu/).